New
HealthMore in Health→
Beyond the Breakthrough: KRAS G12D Inhibitors Show Early Promise in Advanced Cancers
Key Takeaways
- Two early clinical studies of selective KRASG12D inhibitors report encouraging activity in advanced cancers carrying the G12D alteration, according to a Nature Medicine article published online 15 September 2026.
- The piece is framed as moving 'beyond the breakthrough' for RAS-driven cancers, signaling a shift from proving RAS is druggable to extending that capability across variants.
- G12D is a distinct mutation from earlier targeted KRAS variants, requiring its own selective molecules and its own resistance strategy.
- Early-phase activity signals are provisional and must be confirmed through larger trials with longer follow-up.
DE
DT Editorial Team··via nature.com